CN112165957A - proBDNF调节剂在B细胞相关疾病中的用途 - Google Patents

proBDNF调节剂在B细胞相关疾病中的用途 Download PDF

Info

Publication number
CN112165957A
CN112165957A CN201980022274.1A CN201980022274A CN112165957A CN 112165957 A CN112165957 A CN 112165957A CN 201980022274 A CN201980022274 A CN 201980022274A CN 112165957 A CN112165957 A CN 112165957A
Authority
CN
China
Prior art keywords
antibody
probdnf
seq
use according
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980022274.1A
Other languages
English (en)
Inventor
戴茹萍
蔡秀梅
王华茂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Auzone Biological Technology Co ltd
Original Assignee
Shanghai Yile Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yile Biotechnology Ltd filed Critical Shanghai Yile Biotechnology Ltd
Publication of CN112165957A publication Critical patent/CN112165957A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

本发明公开了一种proBDNF调节剂在B细胞相关疾病中的用途。具体来说，本发明公开了一种抑制或激活proBDNF的活性或proBDNF信号通路的试剂在制备调节B淋巴细胞功能的调节剂中的用途。本发明还公开了一种调节剂在制备治疗B淋巴细胞功能紊乱相关疾病的药物中的用途，抗体在制备检测/治疗B淋巴细胞功能紊乱相关疾病的试剂或试剂盒中的用途以及一种预测治疗或预防B淋巴细胞功能紊乱相关疾病的治疗或预防效果的方法。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201980022274.1A 2018-03-26 2019-03-26 proBDNF调节剂在B细胞相关疾病中的用途 Pending CN112165957A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810254609 2018-03-26
CN201810254609X 2018-03-26
PCT/CN2019/079735 WO2019184920A1 (zh) 2018-03-26 2019-03-26 proBDNF调节剂在B细胞相关疾病中的用途

Publications (1)

Publication Number Publication Date
CN112165957A true CN112165957A (zh) 2021-01-01

Family

ID=68062565

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980022274.1A Pending CN112165957A (zh) 2018-03-26 2019-03-26 proBDNF调节剂在B细胞相关疾病中的用途

Country Status (4)

Country Link
US (1) US20220064274A1 (zh)
EP (1) EP3777889A4 (zh)
CN (1) CN112165957A (zh)
WO (1) WO2019184920A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104774264A (zh) * 2014-01-15 2015-07-15 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CN107206078A (zh) * 2014-12-19 2017-09-26 上海易乐生物技术有限公司 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104774264A (zh) * 2014-01-15 2015-07-15 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CN107206078A (zh) * 2014-12-19 2017-09-26 上海易乐生物技术有限公司 特异性结合脑源性神经营养因子前体蛋白的结合分子的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHUHMANN等: "A role for brain-derived neurotrophic factor in B cell development", JOURNAL OF NEUROIMMUNOLOGY, vol. 163, no. 1 *
WOO N.H.等: "Activation of p75NTR by proBDNF facilitates hippocampal long-term depression", NATURE NEUROSCIENCE, vol. 8 *

Also Published As

Publication number Publication date
EP3777889A4 (en) 2022-01-26
US20220064274A1 (en) 2022-03-03
EP3777889A1 (en) 2021-02-17
WO2019184920A1 (zh) 2019-10-03

Similar Documents

Publication Publication Date Title
TWI757304B (zh) Lag-3抗體、其抗原結合片段及其醫藥用途
CN107405397B (zh) 抗tim-3抗体
US11525010B2 (en) Antibodies specific for GUCY2c and uses thereof
WO2017148424A1 (zh) 一种pdl-1抗体、其药物组合物及其用途
TWI290147B (en) Antibodies against insulin-like growth factor I receptor and uses thereof
WO2018036473A1 (zh) 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途
TW201902933A (zh) 對flt3具特異性之抗體及其用途
TW202124438A (zh) 新型抗ｓｉｒｐａ抗體
CN110790839B (zh) 抗pd-1抗体、其抗原结合片段及医药用途
WO2022111425A1 (zh) 与cldn18.2特异性结合的分子
US11434292B2 (en) Antibodies specific for CD3 and uses thereof
AU2003239505A1 (en) Treatment of renal carcinoma using antibodies against the egfr
JP2023106392A (ja) Ｃｄ３抗原結合性断片及びその使用
WO2021115303A1 (zh) 一种抗Claudin18.2单克隆抗体、其制备方法及用途
WO2020056790A1 (zh) 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
CN114127113A (zh) 与钙网蛋白结合的多功能分子及其用途
JPWO2012176765A1 (ja) 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
WO2019109238A1 (en) Anti-cd137 antibodies and uses thereof
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
JP2023179450A (ja) 抗－ヒトプログラム細胞死リガンド－１（ｐｄ－ｌ１）の抗体及びその用途
JP2023520587A (ja) 癌及び感染症の治療のためのＮＫｐ４６に対する抗体及びそのコンストラクト
WO2021093760A1 (zh) 含有TGF-β受体的融合蛋白及其医药用途
EP4182346A1 (en) Therapeutic antibodies and their uses
CN112165957A (zh) proBDNF调节剂在B细胞相关疾病中的用途
TW202102544A (zh) 雙特異性抗體

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231212

Address after: Room 406, Building A7, Bionano Park, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou City, Jiangsu Province, 215000

Applicant after: SUZHOU AUZONE BIOLOGICAL TECHNOLOGY Co.,Ltd.

Address before: 200231 room 320, building 1, 2715 Longwu Road, Xuhui District, Shanghai

Applicant before: SHANGHAI YILE BIOTECHNOLOGY Co.,Ltd.